Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03510650

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Clinical Trial Summary

Hemophagocytic lymphohistiocytosis in adults (HLH) is at 68% mortality whereas 78% of all cases remain undiagnosed though therapies are available which clearly reduce mortality. The investigators aim to systematically investigate this life-threatening hyperinflammatory syndrome in intensive care units (ICU) in order to detect biomarkers that are highly sensitive and highly specific for HLH in ICU compared to patients with sepsis.

Clinical Trial Description

The investigators will draw blood samples of 100 patients at the time of diagnosis (each 50 with suspected or diagnosed HLH/sepsis) to determine a cytokine panel (c reactive protein (CRP), procalcitonin (PCT), interleukin (IL) 1β, IL-6, IL-8, IL-10, IL-18, IL-33, tumor necrosis factor (TNF) α, interferon (IFN) ɣ, soluble IL-2 receptor (sIL-2R), the EBV and CMV viral loads, human immunodeficiency virus (HIV) antibodies and -antigen, perforin, fibrinogen, triglycerides, bilirubin, lactate dehydrogenase, liver transaminases, sodium, serum albumin, electrophoresis, glycosylated ferritin, the microRNAs miR-205-5p, miR-194-5p and miR-30c-5p, perforin, CD107a and high immune status (differential blood count, T cells, B cells, NK cells, T helper cells, cytotoxic T cells, CD4 / CD8 ratio, HLA-DR of CD8 +, CD11a of CD8, CD57 of CD8, CD28 of CD8 +, HLA-DR of monocytes, CD56bright and CD69 of NK cells). The results of this study serve the development of new clinical concepts in order to safely diagnose HLH at an early stage, to distinguish from sepsis and to reduce the fatal consequences. ;

Study Design

Related Conditions & MeSH terms

  • Critical Illness
  • Hemophagocytic Lymphohistiocytosis
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT03510650
Study type Observational
Source Charite University, Berlin, Germany
Contact
Status Completed
Phase
Start date September 11, 2018
Completion date December 26, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT02912702 - L-DEP as an Initial Treatment for EBV-HLH Phase 3
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Completed NCT03259230 - Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT05164978 - DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Terminated NCT01547143 - Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis N/A
Active, not recruiting NCT00006056 - Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT03795909 - Ruxolitinib Combined With Dexamethasone for HLH Phase 1/Phase 2
Recruiting NCT03533790 - DEP-Ru Regimen as a Salvage Therapy for HLH Phase 3
Not yet recruiting NCT05315336 - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT04326348 - A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） Phase 1
Recruiting NCT04551131 - Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Phase 1/Phase 2
Recruiting NCT05546060 - Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH Phase 1
Recruiting NCT05137522 - Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH N/A
Recruiting NCT04120090 - Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis Phase 3